MML Investors Services LLC increased its holdings in shares of Celgene Co. (NASDAQ:CELG) by 7.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 35,014 shares of the biopharmaceutical company’s stock after acquiring an additional 2,555 shares during the period. MML Investors Services LLC’s holdings in Celgene were worth $2,244,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Bruderman Asset Management LLC purchased a new stake in shares of Celgene during the 4th quarter worth $25,000. Murphy Pohlad Asset Management LLC purchased a new stake in Celgene in the fourth quarter valued at $25,000. Athena Capital Advisors LLC purchased a new stake in Celgene in the fourth quarter valued at $27,000. Berman Capital Advisors LLC purchased a new stake in Celgene in the fourth quarter valued at $32,000. Finally, Doyle Wealth Management purchased a new stake in Celgene in the fourth quarter valued at $44,000. Hedge funds and other institutional investors own 74.92% of the company’s stock.
A number of equities research analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $100.00 target price on shares of Celgene in a report on Thursday, January 3rd. William Blair reaffirmed a “buy” rating on shares of Celgene in a report on Thursday, February 28th. Mizuho set a $103.00 price target on shares of Celgene and gave the stock a “buy” rating in a research note on Friday, April 5th. Morgan Stanley dropped their price target on shares of Celgene from $93.00 to $88.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 19th. Finally, Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating in a research report on Monday, December 31st. One equities research analyst has rated the stock with a sell rating, eighteen have given a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $99.41.
Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.32 by $0.07. Celgene had a net margin of 26.48% and a return on equity of 114.66%. The company had revenue of $4.04 billion during the quarter, compared to analyst estimates of $3.98 billion. During the same period last year, the business earned $2.00 EPS. On average, analysts forecast that Celgene Co. will post 10.01 earnings per share for the current fiscal year.
In related news, Director Ernest Mario bought 2,000 shares of the stock in a transaction on Tuesday, February 12th. The shares were purchased at an average price of $89.99 per share, with a total value of $179,980.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James J. Loughlin sold 23,466 shares of the firm’s stock in a transaction dated Thursday, February 7th. The shares were sold at an average price of $87.29, for a total transaction of $2,048,347.14. Following the transaction, the director now directly owns 62,102 shares in the company, valued at approximately $5,420,883.58. The disclosure for this sale can be found here. Company insiders own 0.39% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “MML Investors Services LLC Raises Position in Celgene Co. (CELG)” was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.baseballdailydigest.com/news/2019/04/15/celgene-co-celg-shares-bought-by-mml-investors-services-llc.html.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Further Reading: What are catch-up contributions?
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.